Biotech Distilled

Substack ↗ Subscribe

Subscribe Substack ↗ About

Research Areas Modalities Phases Targets Catalysts Track record Movers The Lead Compound

Home › Targets › EGFRvIII

EGFRvIII (1 companies · 1 programs)

Companies with an active program directed at EGFRvIII.

Black Diamond Therapeutics, Inc. BDTX

silevertinib — Glioblastoma Phase 2

Track record About Feedback Report a bug Substack ↗

This website is an encyclopedia of clinical-stage biotech companies, refreshed weekly. For informational and educational use only — not investment advice. Always verify against primary sources before making decisions.